Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 13,266 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Adult Disease Clear all

Conditions: Opioid Dependence, Buprenorphine Withdrawal Syndrome
Interventions: Lofexidine HCl, Lofexidine-matching sugar pill; Drug
Lead sponsor: USWM, LLC (dba US WorldMeds); Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder
Interventions: ALKS 3831, Olanzapine; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 16 Years to 40 Years
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 25
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Garden Grove, California + 19 more

Conditions: Congenital Heart Defects
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: Not listed
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chemotherapy-induced Thrombocytopenia
Interventions: Romiplostim, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Ogden, Utah • Spokane, Washington

Conditions: Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphomatoid Granulomatosis, Leukemia-Lymphoma, Adult T-Cell
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Brain and Central Nervous System Tumors
Interventions: aldesleukin, muromonab-CD3, therapeutic tumor infiltrating lymphocytes, conventional surgery; Biological · Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 1999
U.S. locations: 3
States / cities: Denver, Colorado

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Not listed
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3)
Interventions: Codrituzumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 2 more

Conditions: Psoriasis
Interventions: Cedirogant, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 31 more

Conditions: Wolfram Syndrome
Interventions: AMX0035; Drug
Lead sponsor: Amylyx Pharmaceuticals Inc.; Industry
Eligibility: 17 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Primary Immunodeficiency
Interventions: Immune Globulin Intravenous, Prometic's Immune Globulin Intravenous 10%; Biological
Lead sponsor: Prometic Biotherapeutics, Inc.; Industry
Eligibility: 2 Years to 80 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 13
States / cities: Irvine, California • Los Angeles, California • Centennial, Colorado + 10 more

Conditions: Neurofibromatosis Type 1, Plexiform Neurofibroma
Interventions: Binimetinib; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Year and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 16 more

Conditions: Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndromes (MDS), Myeloproliferative Disorder, Non-Hodgkin's Lymphoma
Interventions: Conditioning Chemotherapy, Cord blood graft; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Bipolar Disorder
Interventions: lamotrigine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 308
States / cities: Albertville, Alabama • Anniston, Alabama • Birmingham, Alabama + 254 more

Conditions: Heart Failure
Interventions: Dapagliflozin 10mg Tab; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hepatitis C
Interventions: SOF/VEL/VOX, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 43
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more

Conditions: Adult Hepatocellular Carcinoma, Metastatic Malignant Neoplasm in the Liver
Interventions: Image-Guided Adaptive Radiation Therapy, Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Esophageal Cancer, Extragonadal Germ Cell Tumor, Gastric Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions: lapatinib, paclitaxel; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Smoking, Withdrawal Nicotine, ADHD
Interventions: Cigarette smoking, Abstinence; Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 45 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Santa Ana, California

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Depemokimab, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 961 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 56
States / cities: Sheffield, Alabama • Aurora, Colorado • Brooksville, Florida + 48 more

Conditions: Lymphoma
Interventions: bortezomib, gemcitabine hydrochloride; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 3
States / cities: Chicago, Illinois

Conditions: COVID-19
Interventions: Ampion, Standard of Care; Biological · Other
Lead sponsor: Ampio Pharmaceuticals. Inc.; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Conditions: Mild Cognitive Impairment (MCI)
Interventions: AI-Supported Cognitive Rehabilitation; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 65 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pasadena, California

Conditions: HIV Infections
Interventions: Sub C gp140 Vaccine, MF59C.1 Adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Birmingham, Alabama • Nashville, Tennessee • Seattle, Washington

Search by objective public record fields.

Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients

Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder

Heart Failure in Adult Patients With a History of Congenital Heart Disease

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Tissue Collection for Studies of Lymph Cancer

Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors

Viral-Related Neutrophil Response and Condition Severity in People With ARDS

A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis

AMX0035 in Adult Patients With Wolfram Syndrome

Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas

Cord Blood Transplant in Adults With Blood Cancers

Bipolar Study in Adults at Least 18 Years of Age

The Fontan Dapagliflozin Pilot Study

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy

MRI-Guided Stereotactic Body Radiation Therapy in Treating Patients With Liver Metastases or Liver Cancer

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

Association Between Smoking, Brain Activity, Genes, and ADHD

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation

AI-Supported Cognitive Rehabilitation for Older Adults With Mild Cognitive Impairment

Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials